The WHO currently recommends ritonavir-boosted nirmatrelvir (Paxlovid) in patients with nonsevere COVID-19 who are at high risk for hospitalization. The guidelines also strongly recommend against the use of fluvoxamine in patients with nonsevere COVID, unless in the context of a clinical trial. The WHO also strongly recommends against the use of colchicine in patients with nonsevere disease. Anticoagulants (eg, rivaroxaban) are still under investigation for use in COVID-19 and are not included in the WHO guidelines.
Learn more about ritonavir-boosted nirmatrelvir (Paxlovid).
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L. Windle. Rapid Rx Quiz: COVID-19 Treatment Updates - Medscape - Aug 22, 2023.